Comparative Pharmacology
Head-to-head clinical analysis: CLOPRA YELLOW versus MAREZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOPRA YELLOW versus MAREZINE.
CLOPRA-"YELLOW" vs MAREZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clopra (metoclopramide) is a dopamine D2 receptor antagonist and, at higher doses, a serotonin 5-HT4 receptor agonist, which enhances gastrointestinal motility and accelerates gastric emptying. It also has central antiemetic effects via D2 blockade in the chemoreceptor trigger zone.
Marezine (cyclizine) is a piperazine-derivative histamine H1-receptor antagonist with central anticholinergic and antiemetic activity. It competitively blocks H1 receptors in the vestibular apparatus and the chemoreceptor trigger zone (CTZ), suppressing nausea and vomiting. It also has antimuscarinic effects on the vomiting center.
Adult: 25-50 mg orally 3-4 times daily; maximum 200 mg/day. For severe pain: 50-100 mg intramuscularly every 4-6 hours; maximum 300 mg/day.
50 mg intramuscularly or intravenously every 4 to 6 hours as needed for motion sickness; 50 mg orally 30 to 60 minutes before travel, then every 4 to 6 hours up to 150 mg/24h.
None Documented
None Documented
8-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 4-6 hours in adults; prolonged to 8-12 hours in elderly or hepatic impairment
Renal: 70% unchanged, Biliary/Fecal: 20% as metabolites, 10% other
Renal: 70-80% as unchanged drug and metabolites; fecal: ~20%; biliary: minor
Category C
Category C
Antiemetic/Prokinetic Agent
Antiemetic